AI-generated · Based on company filings and platform data · Not investment advice
Eli Lilly (LLY) Q3 2026 Earnings Brief: Revenue $24.40B, +38.6% YoY
Released Oct 29, 2026 (ET)
Quarter: Q3 2026, period ended 2026-09-30; released 2026-10-29 (ET).
In one line: Revenue in the third quarter of 2026 was US$24.40 billion, a year-on-year increase of 38.6%, and adjusted earnings per share were US$7.48, exceeding analysts' consensus expectations by 17.9%.
Key numbers
| Metric | This quarter | Note |
|---|---|---|
| Revenue | $24.40B | YoY +38.6% |
| Adj. EPS vs consensus | $7.48 vs $6.35 | Beat (+17.9%) |
| GAAP diluted EPS | $7.22 | Different basis from consensus |
| Net margin | 26.4% | Net income $6.45B |
| Next-quarter EPS consensus | $11.25 | 17 analysts; revenue consensus $24.70B |
Three things to know
1. Revenue growth mainly comes from increased sales
Revenue for the quarter was US$24.40 billion, a year-on-year increase of 38.6%. The company said the growth was mainly driven by increased sales of Mounjaro and Zepbound, partially offset by lower realized prices. The data is the financial results for this quarter, and the source is the management discussion and analysis (MD&A) in the financial report.
2. Net profit margin reached 26.4%
The net profit margin for the quarter was 26.4%, and net income was US$6.45 billion, an increase of 16% from US$5.58 billion in the same period last year. The company pointed out that the net profit growth was mainly driven by higher gross profit margin, but was partially offset by higher research and development, marketing and administrative expenses. This data is the financial performance of this quarter, and the source is the management discussion and analysis (MD&A) in the financial report.
3. Several new drugs have been approved or entered critical trials
This quarter, the FDA approved insulin efsitora alfa for type 2 diabetes and orforglipron for obesity; at the same time, retatrutide achieved the primary endpoint in the phase III clinical trial of obesity and type 2 diabetes, and several drugs such as eloralintide entered phase III clinical trials. These developments come from an update to the company's clinical development pipeline, covering the first three quarters of 2026
Market reaction
Results were released on 2026-10-29 (ET). From the last pre-report close (2026-10-28, $1286.74) to the close of the first session after the report (2026-10-30, $1415.82), the stock moved +10.03%. The report-day close was $1372.03; the next session closed +3.19% from it (for after-hours releases, this leg better reflects the reaction to the report).
What to watch next
- Pay attention to the revenue and earnings guidance on the fourth quarter 2026 financial report date (February 3, 2027)
- Observe the consensus EPS average of $11.25 for the next quarter.
- Track the progress of regulatory submissions for retatrutide in obesity and type 2 diabetes
- Next report date (platform calendar): 2027-02-03
Sources
- Financials: fundamentals-svc (EDGAR filings, analyst consensus)
- Prices: fundamentals-svc /v1/candles-ondemand
- MD&A source: 10-Q (filed 2026-10-29)
- Company press release (8-K): SEC EDGAR